In the latest installment of Pharmaceutical Research and Manufacturers of America’s (PhRMA) Q&A series on their website, called Conversations , President and CEO John J. Castellani asks: How can we better utilize public-private partnerships to advance translation of science into new medicines for some of our most challenging diseases, such as neurological disorders?
Amy Comstock Rick, chief executive officer of PAN, Randall Rutta, chief strategy officer and executive vice president for public affairs at Easter Seals, and Stevin Zorn, executive vice president and site head of neuroscience R&D at Lundbeck Research USA, provided their perspectives on the question. Amy discussed how strong private-public partnerships provide innovation needed to get much needed drug treatments to the Parkinson’s community. Randall stressed the importance of such collaborations in leading to new life-saving techniques and technologies. Stevin discussed the importance of partnerships in decreasing financial burden and risks associated with important research.
Date originally posted: August 16, 2013.